IDH2 and acute myeloid leukemia: In conclusion, the development of oral, potent, small molecule and mutant specific IDH1 and IDH2 inhibitors represents an early success story of the cancer genome-sequencing era, and signifies an important advance for AML therapy in the era of personalized therapeutics.